ME02682B - Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c - Google Patents
Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa cInfo
- Publication number
- ME02682B ME02682B MEP-2017-85A MEP201785A ME02682B ME 02682 B ME02682 B ME 02682B ME P201785 A MEP201785 A ME P201785A ME 02682 B ME02682 B ME 02682B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- compound
- 6alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 3
- 241000711549 Hepacivirus C Species 0.000 title 1
- LMRCKXYHPYNEJV-UHFFFAOYSA-N piperazine;piperidine Chemical class C1CCNCC1.C1CNCCN1 LMRCKXYHPYNEJV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- -1 -SRe Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical group COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 claims 2
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000000134 cyclophilin inhibitor Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Claims (15)
1. Jedinjenje formule (I): naznačeno time što R1 je izabran od C1-6alkila, C1-6alkoksi, fenila, C3-6cikloalkila, heterociklusa i heteroarila, pri čemu je C1-6alkil izborno supstituisan sa -ORa, amino, -SRe, heterociklusom ili heteroarilom, C1-6alkoksi je izborno supstituisan sa -ORa, i heterociklus je izborno supstituisan sa -ORa, amino, ili -C(O)OC1-6alkilom, ili sa jednim ili dva C1-3alkila; R2 je izabran od vodonika i C1-6alkila; R3 je izabran od vodonika, C1-6alkila, -C(O)OC1-6alkila, -C(O)NRmRn, -C(O)C3-6cikloalkila i -S(O)2C1-3alkila; svaki R4, R5 i R6 su vodonik; ili R4 je izabran od C1-6alkila, -NRbRc, -ORd, -CN, -C(O)NRaRb i halo; i R5 i R6 su vodonik; ili R4 i R5 su nezavisno C1-6alkil ili halo i R6 je vodonik; ili R4 i R5 uzeti zajedno formiraju -O-(CH2)2-O- i R6 je vodonik; ili R4 je vodonik i R5 i R6 uzeti zajedno formiraju -(CH2)n-, gde n je 1, 2, 3 ili 4; ili R4 i R5 su vodonik, i R6 je C1-6alkil, R7 je izabran od halo, C1-3alkila i C1-3alkoksi gde C1-3alkil i C1-3alkoksi su izborno supstituisani sa jednim, dva, tri, četiri ili pet halo; a je 0, 1 ili 2; R8 je C1-3alkil izborno supstituisan sa -ORh; b je 0, 1 ili 2; ili kada b je 2, dva R8 mogu biti spojeni tako da formiraju -(CH2)2-; R9 je C1-3 alkil; c je 0, 1 ili 2; R10 je vodonik, halo ili C1-3alkil supstituisan sa jednim, dva ili tri halo, ili sa - ORh; R11 je izabran od C1-6alkila, C3-10cikloalkila, C1-6alkoksi, -NRfRg, heteroarila, heterociklusa i -CH2-heteroarila; gde: C1-6alkil je izborno supstituisan sa jednim ili dva supstituenta nezavisno izabrana od -ORh, -NRjRk i fenila; C1-6alkoksi je izborno supstituisan sa -ORh ili fenilom; bilo koji C3-10cikloalkil je izborno supstituisan sa jedan ili dva supstituenta nezavisno izabrana od C1-3alkila, -CD3, halo i -ORh; bilo koji heterociklus je izborno supstituisan sa jednim, dva ili tri supstituenta nezavisno izabrana od C1-3alkila, halo, -C(O)OC1-3alkila i -C(O)C1-6alkila, gde je bilo koji -C(O)C1-6alkil izborno supstituisan sa -NHC(O)OC1-3alkilom; bilo koji heteroaril je izborno supstituisan sa jednim ili dva C1-3alkila; R12 je vodonik ili R10 i R12 uzeti zajedno formiraju -CH=CH- ili -(CH2)2-; Ra, Rb, Rc, Rd, Re, Rf, Rh, Rj, Rm i Rn su svaki nezavisno vodonik ili C1-3alkil; Rg je izabran od vodonika, C1-6alkila i C3-6cikloalkila; Rk je izabran od vodonika, -C(O)C1-3alkila, -C(O)OC1-3alkila, -C(O)ONRbRc; i -C(O)NRbRc; i X je N i Y je CH ili X je CH i Y je N; uz uslov da kada je X jednako CH, b je 0 i kada je Y jednako CH, c je 0; ili njegova farmaceutski prihvatljiva so ili stereoizomer.
2. Jedinjenje prema patentnom zahtevu 1 naznačeno time što jedinjenje formule (I) je jedinjenje formule (II):
3. Jedinjenje prema patentnom zahtevu 1 naznačeno time što jedinjenje formule (I) je jedinjenje formule (III):
4. Jedinjenje prema patentnom zahtevu 1 naznačeno time što R1 je izabran od C1-6alkila izborno supstituisanog sa hidroksi ili metoksi, i tetrahidropirana.
5. Jedinjenje prema patentnom zahtevu 1 naznačeno time što R4 je metil, metoksi, fluoro ili -C(O)NH2 i R5 i R6 su vodonik.
6. Jedinjenje prema patentnom zahtevu 1 naznačeno time što R10 i R12 uzeti zajedno formiraju -CH=CH-.
7. Jedinjenje prema patentnom zahtevu 1 naznačeno time što a je 1 ili 2.
8. Jedinjenje prema patentnom zahtevu 1 naznačeno time što jedinjenje je jedinjenje formule (IV): gde: R1 je izabran od C1-6alkila izborno supstituisanog sa hidroksi ili metoksi, tetrahidropirana i fenila; R2 je vodonik; R3 je -C(O)OC1-6alkil; R7 je izabran od fluoro, hloro, -CF3 i -OCF3; R11 je izabran od C1-6alkila, C3-6cikloalkila i C1-6alkoksi gde C1-6alkil je izborno supstituisan sa -ORh i C3-6cikloalkil je izborno supstituisan sa jednim ili dva C1-3alkila; R10 je vodonik, hloro ili fluoro; i a je 1 ili 2; ili njegova farmaceutski prihvatljiva so.
9. Jedinjenje prema patentnom zahtevu 1 naznačeno time što jedinjenje je jedinjenje formule (V): gde: R1 je izabran od C1-6alkila izborno supstituisanog sa hidroksi ili metoksi, tetrahidropirana i fenila; R2 je vodonik; R3 je -C(O)OC1-6alkil; R7 je izabran od fluoro, hloro, -CF3 i -OCF3; R11 je izabran od C1-6alkila, C3-6cikloalkila i C1-6alkoksi gde C1-6alkil je izborno supstituisan sa -ORh i C3-6cikloalkil je izborno supstituisan sa jednim ili dva C1-3alkila; i a je 1 ili 2; ili njegova farmaceutski prihvatljiva so.
10. Jedinjenje prema patentnom zahtevu 8 ili patentnom zahtevu 9 naznačeno time što R11 je izabran od terc-butila, ciklopropila, 2,2-dimetilciklopropila, ciklobutila, 2,2-dimetilciklobutila, 3-hidroksi-2,2-dimetilpropila i terc-butoksi.
11. Jedinjenje prema patentnom zahtevu 1 naznačeno time što je jedinjenje izabrano od i njegova farmaceutski prihvatljiva so.
12. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva 1 do 11 i farmaceutski prihvatljiv nosač, i koja izborno dalje sadrži jedno ili više drugih terapeutskih agenasa korisnih za lečenje infekcija virusom hepatitisa C.
13. Famaceutska kompozicija prema patentnom zahtevu 12 naznačena time što jedan ili više drugih terapeutskih agenasa je izabran od inhibitora HCV NS3 proteaze i nukleozidnih i nenukleozidnih inhibitora polimeraze HCV NS5B polimeraze.
14. Jedinjenje prema bilo kom od patentnih zahteva 1 do 11 za upotrebu u lečenju virusne infekcije hepatitisa C kod sisara.
15. Jedinjenje za upotrebu prema patentnom zahtevu 14 naznačeno time što je jedinjenje korišćeno u kombinaciji sa jednim ili više drugih terapeutskih agenasa izabranih od inhibitora HCV NS3 proteaze, nukleozidnih i nenukleozidnih inhibitora HCV NS5B polimeraze, interferona i pegilovanih interferona, inhibitora ciklofilina, inhibitora HCV NS5A i ribavirina i srodnih nukleozidnih analoga.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637959P | 2012-04-25 | 2012-04-25 | |
| US201361774033P | 2013-03-07 | 2013-03-07 | |
| EP13720201.6A EP2850075B1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
| PCT/US2013/037920 WO2013163262A1 (en) | 2012-04-25 | 2013-04-24 | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02682B true ME02682B (me) | 2017-06-20 |
Family
ID=48237291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-85A ME02682B (me) | 2012-04-25 | 2013-04-24 | Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9206159B2 (me) |
| EP (1) | EP2850075B1 (me) |
| JP (1) | JP6069491B2 (me) |
| CN (1) | CN104302639B (me) |
| CA (1) | CA2869640C (me) |
| CY (1) | CY1118920T1 (me) |
| DK (1) | DK2850075T3 (me) |
| ES (1) | ES2624846T3 (me) |
| HR (1) | HRP20170471T1 (me) |
| HU (1) | HUE032173T2 (me) |
| LT (1) | LT2850075T (me) |
| ME (1) | ME02682B (me) |
| PL (1) | PL2850075T3 (me) |
| PT (1) | PT2850075T (me) |
| RS (1) | RS55864B1 (me) |
| SI (1) | SI2850075T1 (me) |
| WO (1) | WO2013163262A1 (me) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108794454B (zh) * | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN107814789B8 (zh) * | 2017-11-27 | 2021-01-01 | 常州寅盛药业有限公司 | 一种达卡他韦起始原料的合成方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20180028070A (ko) | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| EP2473056A4 (en) | 2009-09-04 | 2013-02-13 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| EP2475254A4 (en) * | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2013515746A (ja) | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| AU2011224698A1 (en) | 2010-03-09 | 2012-11-01 | Merck Sharp & Dohme Corp. | Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| JP5891235B2 (ja) * | 2010-11-04 | 2016-03-22 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルスの新規阻害剤 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20140091036A (ko) | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
| JP6069492B2 (ja) * | 2012-04-25 | 2017-02-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルス阻害剤 |
-
2013
- 2013-04-24 SI SI201330640A patent/SI2850075T1/sl unknown
- 2013-04-24 DK DK13720201.6T patent/DK2850075T3/en active
- 2013-04-24 HU HUE13720201A patent/HUE032173T2/en unknown
- 2013-04-24 HR HRP20170471TT patent/HRP20170471T1/hr unknown
- 2013-04-24 EP EP13720201.6A patent/EP2850075B1/en active Active
- 2013-04-24 CN CN201380021717.8A patent/CN104302639B/zh not_active Expired - Fee Related
- 2013-04-24 CA CA2869640A patent/CA2869640C/en not_active Expired - Fee Related
- 2013-04-24 PT PT137202016T patent/PT2850075T/pt unknown
- 2013-04-24 PL PL13720201T patent/PL2850075T3/pl unknown
- 2013-04-24 RS RS20170354A patent/RS55864B1/sr unknown
- 2013-04-24 US US13/869,199 patent/US9206159B2/en not_active Expired - Fee Related
- 2013-04-24 ES ES13720201.6T patent/ES2624846T3/es active Active
- 2013-04-24 WO PCT/US2013/037920 patent/WO2013163262A1/en not_active Ceased
- 2013-04-24 JP JP2015509099A patent/JP6069491B2/ja not_active Expired - Fee Related
- 2013-04-24 ME MEP-2017-85A patent/ME02682B/me unknown
- 2013-04-24 LT LTEP13720201.6T patent/LT2850075T/lt unknown
-
2017
- 2017-05-17 CY CY20171100520T patent/CY1118920T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2869640A1 (en) | 2013-10-31 |
| US9206159B2 (en) | 2015-12-08 |
| US20130287730A1 (en) | 2013-10-31 |
| EP2850075B1 (en) | 2017-02-22 |
| PL2850075T3 (pl) | 2017-08-31 |
| SI2850075T1 (sl) | 2017-06-30 |
| ES2624846T3 (es) | 2017-07-17 |
| CA2869640C (en) | 2018-03-20 |
| DK2850075T3 (en) | 2017-05-22 |
| CN104302639B (zh) | 2017-03-29 |
| CN104302639A (zh) | 2015-01-21 |
| LT2850075T (lt) | 2017-05-10 |
| EP2850075A1 (en) | 2015-03-25 |
| WO2013163262A1 (en) | 2013-10-31 |
| HUE032173T2 (en) | 2017-09-28 |
| CY1118920T1 (el) | 2018-01-10 |
| RS55864B1 (sr) | 2017-08-31 |
| HRP20170471T1 (hr) | 2017-06-02 |
| JP2015514807A (ja) | 2015-05-21 |
| PT2850075T (pt) | 2017-05-02 |
| JP6069491B2 (ja) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02875B (me) | Inhibitori hcv polimeraze | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20220920T1 (hr) | Pirolo[1,2-f][1,2,4]triazini koji su korisni za liječenje infekcija respiratornim sincicijalnim virusom | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| JP2011079828A5 (me) | ||
| BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20100209T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| JP2013521279A5 (me) | ||
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| JP2016518359A5 (me) | ||
| ME02835B (me) | Antivirusna rsv jedinjenja | |
| HRP20201023T1 (hr) | Dioksilan analozi uridina za liječenje raka | |
| JP2016501185A5 (me) | ||
| HRP20141169T1 (hr) | Makrocikliäśki inhibitori serin proteaze hepatitisa c | |
| RU2015148010A (ru) | Высокоактивное производное нуклеозида для лечения hcv | |
| UA116616C2 (uk) | Інгібітори hcv серинової протеази, отримані з макроциклічного проліну | |
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. |